Date: 2015-03-26
Type of information: Joint-venture agreement
Compound:
Company: Stada (Germany) Hetero Labs (India)
Therapeutic area:
Type agreement: joint-venture agreement
Action mechanism:
Disease:
Details: * On March 26, 2015, Stada Arzneimittel announced that it has signed a letter of intent with Indian pharmaceutical company Hetero Labs for the founding of a contractual joint venture. The planned cooperation initially calls for Stada to procure selected oncology products at attractive conditions. These relate to both existing products as well as new developments. An expansion of the cooperation into further areas is imaginable at a later point in time. Stada and Hetero Labs have been working together successfully for a number of years – especially in the areas of active ingredient procurement and in-licensing. While the Indian pharmaceutical company is active mainly in India and in the USA, the focus of Stada\'s business activities is in Europe. It is therefore planned that Stada, within the framework of a contractual joint venture, will take over marketing exclusively in Europe and in a sub-license in further regions outside of India and the USA. As part of the cooperation, the financial investment on the part of Stada would be relatively limited. Stada will, among other things, contribute its broad marketing platform and approval expertise to the cooperation. Sales would be allocated in equal parts to Stada and Hetero. “Through this partnership with STADA, Hetero will provide a complete range of oncology products to European markets. As Hetero is vertically integrated with its API’s we believe the collaboration will mutually benefit both companies”, says Dr. B.P.S. Reddy, Chairman Hetero group. The current schedule calls for the final joint venture contracts to be signed in the course of 2015.
Financial terms:
Latest news:
